• Something wrong with this record ?

Efficacy and safety of SENS-401 in sudden sensorineural hearing loss: The AUDIBLE-S randomized placebo-controlled phase IIb trial

I. Braverman, M. Elziere, Z. Komazec, M. Cohen-Vaizer, MT. Kalcioglu, V. Chrobok, I. Kazmer, O. Hilly, MJ. Esteve-Fraysse, I. Doweck, AL. Glotin, S. Fitoussi, J. Laredo, G. Honnet

. 2024 ; 45 (6) : 104480. [pub] 20240808

Language English Country United States

Document type Journal Article, Randomized Controlled Trial, Clinical Trial, Phase II, Multicenter Study

Persistent link   https://www.medvik.cz/link/bmc25003697

PURPOSE: Safety and efficacy of SENS-401, a serotonin type 3 (5-HT3) receptor antagonist and calcineurin inhibitor, in patients with acute sudden sensorineural hearing loss (SSNHL). METHODS: Multicentre randomized, double blind, placebo-controlled trial enrolled adult subjects with sudden sensorineural hearing loss (SSNHL) or unilateral/bilateral acute acoustic trauma leading to SSNHL within 96 h of disease onset. Subjects were randomly assigned to one of the three oral dose groups: 29 mg, 43.5 mg or placebo given twice daily for 28 days. The primary endpoint was the change from baseline in Pure Tone Average (PTA) in the affected ear to the end of treatment visit (day 28). Subjects were further followed up 8 weeks after the end of the treatment period (day 84). RESULTS: A total of 115 subjects were randomized. SENS-401 was well tolerated. Although the primary efficacy endpoint was not met at day 28, post-hoc analyses revealed clinically significant and meaningful efficacy outcomes with SENS-401 when compared to placebo in a substantial group of participants diagnosed with idiopathic SSNHL and who had received corticosteroid treatment. Notable improvements were observed in the PTA change from baseline, the complete hearing recovery rate, and the Word Recognition Score (WRS), particularly at day 84. The responder rate consistently favored treated subjects over those who received the placebo. CONCLUSION: While the primary endpoint was not achieved at the end of the treatment period, the study revealed consistently positive efficacy results of clinical relevance in patients with idiopathic SSNHL who received SENS-401, particularly in the 8-weeks follow-up phase after the completion of the treatment.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25003697
003      
CZ-PrNML
005      
20250206104624.0
007      
ta
008      
250121s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.amjoto.2024.104480 $2 doi
035    __
$a (PubMed)39173396
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Braverman, Itzhak $u Hillel Yaffe Medical Centre, Ha'shalom, PObox 169, 38100 Hadera, Israel. Electronic address: braverman@hy.health.gov.il
245    10
$a Efficacy and safety of SENS-401 in sudden sensorineural hearing loss: The AUDIBLE-S randomized placebo-controlled phase IIb trial / $c I. Braverman, M. Elziere, Z. Komazec, M. Cohen-Vaizer, MT. Kalcioglu, V. Chrobok, I. Kazmer, O. Hilly, MJ. Esteve-Fraysse, I. Doweck, AL. Glotin, S. Fitoussi, J. Laredo, G. Honnet
520    9_
$a PURPOSE: Safety and efficacy of SENS-401, a serotonin type 3 (5-HT3) receptor antagonist and calcineurin inhibitor, in patients with acute sudden sensorineural hearing loss (SSNHL). METHODS: Multicentre randomized, double blind, placebo-controlled trial enrolled adult subjects with sudden sensorineural hearing loss (SSNHL) or unilateral/bilateral acute acoustic trauma leading to SSNHL within 96 h of disease onset. Subjects were randomly assigned to one of the three oral dose groups: 29 mg, 43.5 mg or placebo given twice daily for 28 days. The primary endpoint was the change from baseline in Pure Tone Average (PTA) in the affected ear to the end of treatment visit (day 28). Subjects were further followed up 8 weeks after the end of the treatment period (day 84). RESULTS: A total of 115 subjects were randomized. SENS-401 was well tolerated. Although the primary efficacy endpoint was not met at day 28, post-hoc analyses revealed clinically significant and meaningful efficacy outcomes with SENS-401 when compared to placebo in a substantial group of participants diagnosed with idiopathic SSNHL and who had received corticosteroid treatment. Notable improvements were observed in the PTA change from baseline, the complete hearing recovery rate, and the Word Recognition Score (WRS), particularly at day 84. The responder rate consistently favored treated subjects over those who received the placebo. CONCLUSION: While the primary endpoint was not achieved at the end of the treatment period, the study revealed consistently positive efficacy results of clinical relevance in patients with idiopathic SSNHL who received SENS-401, particularly in the 8-weeks follow-up phase after the completion of the treatment.
650    _2
$a lidé $7 D006801
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a percepční nedoslýchavost $x farmakoterapie $7 D006319
650    _2
$a lidé středního věku $7 D008875
650    12
$a náhlá nedoslýchavost $x farmakoterapie $7 D003639
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a vztah mezi dávkou a účinkem léčiva $7 D004305
650    _2
$a audiometrie čistými tóny $7 D001301
650    _2
$a aplikace orální $7 D000284
650    _2
$a následné studie $7 D005500
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a klinické zkoušky, fáze II $7 D017427
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Elziere, Maya $u Hôpital Européen de Marseille, 6 rue Désirée Clary, 13003 Marseille, France
700    1_
$a Komazec, Zoran $u H Medical Faculty, University of Novi Sad, Serbia
700    1_
$a Cohen-Vaizer, Mauricio $u 6 Ha'Aliya Ha'shniya Street, POB 9602, 3109601 Haifa, Israel
700    1_
$a Kalcioglu, Mahmut Tayyar $u Istambul Medeyinet University Goztepe, Pr Dr Suleyman Yalcin City Hospital, Department of Otorhinolaryngology, Istambul, Turkey
700    1_
$a Chrobok, Viktor $u Fakultni nemocnice Hradec Kralove -Klinika otorinolaryngologie a chirurgie hlavy a krku, Sokolská 581, 500 05 Hradec Králové, Czech Republic
700    1_
$a Kazmer, Igor $u Janosikovo Nabrezie 1212, Liptovsky Mikulas 03101, Slovakia
700    1_
$a Hilly, Ohad $u Rabin Medical Center, Zeev Jabotinsky 39, Petach Tikva 4341492, Israel
700    1_
$a Esteve-Fraysse, Marie Jose $u Centre d'exploration fonctionnelle d'otoneurologie, 10 rue Falguieres, 75015 Paris. France
700    1_
$a Doweck, Ilana $u Lady Davis Carmel Medical Center, Michal Street 7, Haifa 3436212, Israel
700    1_
$a Glotin, Anne-Lise $u 375 rue du Professeur Joseph Blayac, 34080 Montpellier, France
700    1_
$a Fitoussi, Serge $u 375 rue du Professeur Joseph Blayac, 34080 Montpellier, France. Electronic address: serge.fitoussi@sensorion-pharma.com
700    1_
$a Laredo, Judith $u 375 rue du Professeur Joseph Blayac, 34080 Montpellier, France
700    1_
$a Honnet, Geraldine $u 375 rue du Professeur Joseph Blayac, 34080 Montpellier, France
773    0_
$w MED00149991 $t American journal of otolaryngology $x 1532-818X $g Roč. 45, č. 6 (2024), s. 104480
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39173396 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250121 $b ABA008
991    __
$a 20250206104620 $b ABA008
999    __
$a ok $b bmc $g 2263452 $s 1239704
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 45 $c 6 $d 104480 $e 20240808 $i 1532-818X $m American journal of otolaryngology $n Am J Otolaryngol $x MED00149991
LZP    __
$a Pubmed-20250121
Back

Find record

Citation metrics

Archiving options